Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1 Jun 2025 at 11:57pm
Tarlatamab, a bispecific delta-like ligand 3?directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer ...
The New England Journal of Medicine | Research & Review Articles on ...
7 Dec 2025 at 11:19pm
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
10 Dec 2024 at 11:55pm
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ER? ...
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
22 Apr 2025 at 11:55pm
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP...
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
29 May 2025 at 11:54pm
Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E?mutated metastatic ...
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
6 Feb 2025 at 11:58pm
Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day ...
Phase 3 Trial of Semaglutide in Metabolic Dysfunction?Associated ...
29 Apr 2025 at 11:54pm
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction?associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...
Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...
22 Apr 2025 at 11:55pm
Background Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited.
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
31 May 2025 at 11:59pm
Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise ...
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream ...
19 Nov 2024 at 11:58pm
Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, non...
WHAT IS THIS? This is an unscreened compilation of results from several search engines. The sites listed are not necessarily recommended by Surfnetkids.com.
1 Jun 2025 at 11:57pm
Tarlatamab, a bispecific delta-like ligand 3?directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer ...
The New England Journal of Medicine | Research & Review Articles on ...
7 Dec 2025 at 11:19pm
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
10 Dec 2024 at 11:55pm
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ER? ...
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
22 Apr 2025 at 11:55pm
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP...
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
29 May 2025 at 11:54pm
Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E?mutated metastatic ...
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
6 Feb 2025 at 11:58pm
Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day ...
Phase 3 Trial of Semaglutide in Metabolic Dysfunction?Associated ...
29 Apr 2025 at 11:54pm
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction?associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...
Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...
22 Apr 2025 at 11:55pm
Background Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited.
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
31 May 2025 at 11:59pm
Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise ...
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream ...
19 Nov 2024 at 11:58pm
Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, non...
WHAT IS THIS? This is an unscreened compilation of results from several search engines. The sites listed are not necessarily recommended by Surfnetkids.com.
